DA. Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib.
negative myeloproliferative neoplasm (MPN) chronic neutrophilic leukemia (CNL) as a distinct entity based on the features of an increased white blood cell count (WBC) with a preponderance of neutrophils, no increase in blasts, no dysplasia and the exclusion of other clonal or non-clonal etiologies (1) . More recently, it was observed that CSF3R is recurrently mutated in patients with CNL (2) , which has led to the addition of this finding to the diagnostic criteria for CNL in the most recent 2016 WHO classification of myeloid neoplasms(3). CSF3R mutations have therapuetic implications; membrane proximal mutations result in activated signaling through the JAK-STAT pathway, and anectodal reports suggest the JAK1/2 inhibitor ruxolitinib may have efficacy in this setting (2, 4, 5) .
Here, we report the case of a 69-year-old CNL patient treated with ruxolitinib. He had no significant past medical history and four months prior to presentation developed increasing fatigue, abdominal distention and easy bruising. He was noted to have a WBC of 100.1x10 Re-analysis of the sequencing data to investigate mutations at or below the 7% clinically reportable cutoff did reveal evidence of the CSF3R and SETBP1 mutations, at 7% and 6%, respectively (Table 1 ). In addition, re-analysis of the sequencing data was also performed on the original bone marrow aspirate, revealing the sub-clinical presence of the RUNX1 mutation that was not originally detected, but no evidence for the presence of the GATA2 or KIT mutations that were subsequently noted ( Table 1 ).
The patient was admitted for respiratory failure from sepsis, developed multiorgan failure and expired.
The clinical experience with ruxolitinib in CSF3R-mutated myeloproliferative neoplasms is limited, but anectodal reports suggest it can be active (2, 4, 5) , and this is the focus of an ongoing clinical trial (NCT02092324). Ninety-percent of CNL patients and about 40% of atypical chronic myeloid leukemia (aCML) patients have mutations in CSF3R; membrane proximal mutations activate JAK/STAT signaling(2), suggesting the JAK1/2 inhibitor ruxolitinib may be active, supported by pre-clinical studies (6) .
At diagnosis our patient had clinically detectable mutations in CSF3R and SETBP1, among the most commonly mutated genes in BCR-ABL1 negative myeloproliferative neoplasms (2, 7) . Retrospectively, the presence of the RUNX1 mutation, at low levels, was appreciated. His clinical and laboratory response with ruxolitinib ended abruptly; repeated genomic analysis at the time of disease progression revealed the development of new mutations in GATA2 and KIT, neither of which were detected at the time of diagnosis. The development of these mutations, and/or the increased allele burden of RUNX1, were possible contributors to ruxolitinib resistance and subsequent disease progression. KIT is involved in activated signaling (8) , while GATA2 and RUNX1 are myeloid transcription factors; in addition, RUNX1 has been identified as a driver mutation in the evolution of a myeloproliferative neoplasm to acute myeloid leukemia (9) . The proportional decreased allele frequenices for CSF3R and SETBP1 after treatment with ruxolitnib (Table 1) suggest that a single sub-clone harbored these mutations and was suscepitble to inhibition of the JAK/STAT signaling pathway, as was predicted. Although a previous case report did not show a reduction in CSF3R-T618I allele frequency in a patient who clinically responded to ruxolitinib(5), it is possible that depth of responses may vary and that this patient experienced a deeper response.
In conclusion, we report here for the first time changes in the allele frequencies of CSF3R-T618I and SETBP1-G870S with response to ruxolitnib, as well as insights into the clonal evolution of CNL under selective pressure from ruxolitinib. Ruxolitinib has activity in CSF3R-mutated myeloproliferative neoplasms, and can decrease the allele frequency of this mutation and others within a sub-clone. Although from this case we cannot state definitively whether disease progression was independent of treatment or due to selective pressure from ruxolitinib, we show that clonal evolution in CNL can occur and can be explained by the acqusition of driver gene mutations. Similar studies with more CNL patients undergoing treatment with targeted therapies are warranted to further understand this process. 
